Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
5
Recruiting, any sponsor type, condition "rosacea"
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed138
5 trials
Showing 1 to 5, recently updated first.
- A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Patients With Papulopustular Rosacea (PPR)Pivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07681271 · 100 participants (planned) · Start Jul 30, 2026 · Primary completion Dec 7, 2027
Drug: LOU064; Placebo · For: Papulopustular Rosacea
Sites: El Paso, Texas; Sofia, Bulgaria; London, Canada · 17 sites in all
University Hospital Schleswig-HolsteinAcademic, hospital or other
NCT05928169 · 1,000 participants (planned) · Start May 1, 2023 · Primary completion Apr 30, 2032
Drug: Topical and systemic drugs · For: Atopic Dermatitis; Psoriasis; Lichen Planus and 5 more
Sites: Kiel, Germany
The Fourth Affiliated Hospital of Zhejiang University School of MedicineAcademic, hospital or other
NCT07343635 · 186 participants (planned) · Start Feb 1, 2026 · Primary completion Jul 1, 2027
Drug: Doxycycline; Hydroxychloroquine and 1 more · For: Erythematotelangiectatic Rosacea
Sites: Yiwu, China
Wright State UniversityAcademic, hospital or other
NCT06312813 · 48 participants (planned) · Start Feb 27, 2024 · Primary completion Dec 1, 2028
Drug: Imipramine; Amitriptyline and 1 more · For: Rosacea
Sites: Fairborn, Ohio
Narrows Institute for Biomedical ResearchAcademic, hospital or other
NCT06952517 · 20 participants (planned) · Start Mar 14, 2025 · Primary completion Sep 1, 2025
Drug: Clascoterone Cream 1% · For: Papular-pustular Rosacea; Papulopustular Rosacea (PPR); Papulopustular Rosacea
Sites: Brooklyn, New York
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.